Chronic Ang-1-7 treatment opposes diabetes-induced signaling changes in (a) ERK1/2, p38 MAPK, ROCK2 and (b) in eNOS and NF-kB in the mesenteric vascular bed.

<p><b>(a)</b> Representative Western blot (panel i) showing the levels of phosphorylated (p-) or total (t) for ERK1/2, p38 MAPK, ROCK2 proteins and β-actin in the isolated mesenteric bed from normal controls (C), diabetic (D) and diabetic animals treated for 4 weeks with Ang-(1–7) (+A1-7) or AG825 (+AG825). Densitometry histograms showing band intensity ratios for levels of phosphorylated to total protein as stated following normalization of each to actin and presented as relative to control value (panels ii-iv). (b) Representative Western blot (panel i) showing the levels of phosphorylated (p-) or total (t) for eNOS and IkB proteins and β-actin in the isolated mesenteric bed from normal controls (C), diabetic (D) and diabetic animals treated for 4 weeks with Ang-(1–7) (+A1-7) or AG825 (+AG825). Densitometry histograms showing band intensity ratios for levels of phosphorylated (p-) or total (t) proteins normalized to actin and presented as relative to control or for ratio of phosphorylated to total protein as stated following normalization to actin and presented as relative to control value (ii-vii). n = 6; mean ± SD. *Indicates significantly different (P < 0.05) mean values from normal non-diabetic rats (C), whereas # indicates significantly different mean values (P < 0.05) from diabetic rats (D).